top of page

When will the Ellipse SCS platform be available?

Answer

"Good things take time, great things take a little longer."

We are feverishly working with our manufacturing partners to bring Ellipse technology to market as soon as possible. The U.S. Food and Drug Administration has granted our StimuLux technology their Breakthrough Device Designation which expedites our regulatory review. We anticipate U.S. market entry in 2027.

DISCLAIMER

Wavegate's Ellipse platform with StimuLux technology has not yet been evaluated by the U.S. Food and Drug Administration and is not currently available for sale in the United States.

  • Instagram
  • Grey Facebook Icon
  • Grey Twitter Icon

© 2024 by WAVEGATE CORPORATION

Ellipse, StimuLux, and Active Loop are trademarks of Wavegate Corporation

Ellipse platform technology is covered by multiple US and International issued patents and patents pending.

​

NEWS RELEASES

Sign up below to receive updates on Wavegate's Ellipse Technology!

Thanks for submitting!

bottom of page